Nasopharyngeal carcinoma future or investigational therapies: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Nasopharyngeal carcinoma}} | {{Nasopharyngeal carcinoma}} | ||
{{CMG}} {{AE}}{{Faizan}} | |||
==Overview== | |||
Treatments under clinical evaluation for patients with [[nasopharyngeal cancer]] include dose escalation with new radiation therapy techniques such as stereotactic radiation therapy boost and [[brachytherapy]].<ref name="pmid10571198">{{cite journal| author=Tate DJ, Adler JR, Chang SD, Marquez S, Eulau SM, Fee WE et al.| title=Stereotactic radiosurgical boost following radiotherapy in primary nasopharyngeal carcinoma: impact on local control. | journal=Int J Radiat Oncol Biol Phys | year= 1999 | volume= 45 | issue= 4 | pages= 915-21 | pmid=10571198 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10571198 }} </ref> | |||
==Future Treatment== | |||
*Treatments under clinical evaluation for patients with [[nasopharyngeal cancer]] include the following:<ref name="pmid10571198">{{cite journal| author=Tate DJ, Adler JR, Chang SD, Marquez S, Eulau SM, Fee WE et al.| title=Stereotactic radiosurgical boost following radiotherapy in primary nasopharyngeal carcinoma: impact on local control. | journal=Int J Radiat Oncol Biol Phys | year= 1999 | volume= 45 | issue= 4 | pages= 915-21 | pmid=10571198 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10571198 }} </ref> | |||
**Dose escalation with new radiation therapy techniques such as stereotactic radiation therapy boost | |||
**[[Brachytherapy]] | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Types of cancer]] | [[Category:Types of cancer]] | ||
Revision as of 12:29, 24 September 2015
|
Nasopharyngeal carcinoma Microchapters |
|
Differentiating Nasopharyngeal carcinoma from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Nasopharyngeal carcinoma future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Nasopharyngeal carcinoma future or investigational therapies |
|
FDA on Nasopharyngeal carcinoma future or investigational therapies |
|
CDC on Nasopharyngeal carcinoma future or investigational therapies |
|
Nasopharyngeal carcinoma future or investigational therapies in the news |
|
Blogs on Nasopharyngeal carcinoma future or investigational therapies |
|
Risk calculators and risk factors for Nasopharyngeal carcinoma future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Faizan Sheraz, M.D. [2]
Overview
Treatments under clinical evaluation for patients with nasopharyngeal cancer include dose escalation with new radiation therapy techniques such as stereotactic radiation therapy boost and brachytherapy.[1]
Future Treatment
- Treatments under clinical evaluation for patients with nasopharyngeal cancer include the following:[1]
- Dose escalation with new radiation therapy techniques such as stereotactic radiation therapy boost
- Brachytherapy
References
- ↑ 1.0 1.1 Tate DJ, Adler JR, Chang SD, Marquez S, Eulau SM, Fee WE; et al. (1999). "Stereotactic radiosurgical boost following radiotherapy in primary nasopharyngeal carcinoma: impact on local control". Int J Radiat Oncol Biol Phys. 45 (4): 915–21. PMID 10571198.